BACKGROUND Randomized data on statins for primary prevention in older persons are limited, and the relative hazard of cardiovascular disease associated with an elevated cholesterol level weakens with advancing age. OBJECTIVE To assess the efficacy and safety of rosuvastatin in persons 70 years or older. DESIGN Secondary analysis of JUPITER (Justification for the Use of statins in Prevention...

BACKGROUND Statins reduce adverse cardiovascular outcomes and slow the progression of coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) cholesterol. However, few studies have either assessed the ability of intensive statin treatments to achieve disease regression or compared alternative approaches to maximal statin administration. METHODS We perfo...

OBJECTIVE To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses. RESEARCH DESIGN AND METHODS Double-blind, multicenter, 6-week, parallel-group study in hypercholesterolemic patients (n = 2959). Patients were randomized based on stratification by low-density lipo...

1 The Lancet. The statin wars: why AstraZeneca must retreat. Lancet 2003; 362: 1341. 2 Uretsky BG, Thygesen K, Armstrong PW, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611–16. 3 Krum H, McMurray JJV. Statins and chronic heart failure: do we need...

Pharmacology: Rosuvastatin selectively and competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the production of mevalonate, a cholesterol precursor. Rosuvastatin has high activity in, uptake into, and selectivity for the liver, the target organ. It enhances uptake and catabolism of LDL by increasing hepatic LDL receptor levels. It also inhibits the hepatic VLDL synthesis, red...

A simple, precise and accurate reversed-phase liquid chromatographic method has been developed for the simultaneous estimation of Rosuvastatin and Fenofibrate in tablet formulations. The chromatographic separation was achieved on (Inertsil ODS, 250 x 4.6mm, 5μ column) analytical column. And mobile phase as mixture of Water (pH adjusted to 2.5 with ortho phosphoric acid) and acetonitrile in rati...

Rosuvastatin represents the latest inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase introduced in clinical practice for the treatment of hypercholesterolemia. In comparative trials, across dose ranges this statin reduced low-density lipoprotein (LDL) cholesterol and total cholesterol significantly more than atorvastatin, simvastatin, and pravastatin, and triglycerides sign...

Methods The MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY II) trial examined the effects of statin treatment in patients with high coronary heart disease (CHD) risk, LDL-C 130 and 250 mg/dl, and triglycerides 400 mg/dl. Therapy consisted of rosuvastatin (10 or 20 mg), atorvastatin (10 or 20 mg), or simvastatin (20 or 40 mg). The apoB and LDL-C or non–HDL-C...

Downloa 3. Andreou I, Tousoulis D, Miliou A, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010;210:194–8. 4. Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact o...

METHODS: We measured plasma PCSK9 concentrations by ELISA at baseline and at 1 year in 500 men and 500 women participating in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial that randomly allocated participants to rosuvastatin 20 mg daily or placebo. We also evaluated rs11591147, a single nucleotide polymorphism known to have an ...